PCSA — Processa Pharmaceuticals Balance Sheet
0.000.00%
- $4.66m
- -$4.25m
- 24
- 48
- 37
- 29
Annual balance sheet for Processa Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.692 | 15.4 | 16.5 | 6.5 | 4.71 |
Net Total Receivables | 0 | 0.232 | 0.07 | — | — |
Prepaid Expenses | |||||
Total Current Assets | 1.01 | 16.2 | 18.3 | 8.39 | 5.63 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.228 | 0.159 | 0.074 | 0.228 | 0.149 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 10.9 | 25.2 | 26.5 | 8.62 | 5.79 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 1.19 | 1.22 | 0.971 | 0.999 | 0.731 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Other Liabilities | |||||
Total Liabilities | 2.87 | 2.27 | 0.978 | 1.15 | 0.797 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 8.01 | 22.9 | 25.5 | 7.47 | 4.99 |
Total Liabilities & Shareholders' Equity | 10.9 | 25.2 | 26.5 | 8.62 | 5.79 |
Total Common Shares Outstanding |